Evaluation of a production ready portable, Point-of-Need Platform (instrument and reagents), direct from nasal swab test for the molecular diagnostic detection of COVID-19 infection.
- Funded by European Commission
- Total publications:1 publications
Grant number: 101005075
Grant search
Key facts
Disease
COVID-19Start & end year
20202022Known Financial Commitments (USD)
$941,364Funder
European CommissionPrincipal Investigator
CHARREL RémiResearch Location
FranceLead Research Institution
UNIVERSITE D'AIX MARSEILLEResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Diagnostics
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
This project focuses on rapid (40min), simple, Point-of-Need COVID-19 testing, e.g. surgery/home (via first responders)/transit points of entry. BG Research (BGR) has developed direct from crude sample detection of viral pathogens 'Äì the QuRapID-XF technology, removing requirement for nucleic acid extraction, expert users or a laboratory; results delivered while you wait. Tests utilise the Gold Standard polymerase chain technology as current clinical reference tests, but using our novel reagent, directly breaking open the virus and a single enzyme system that is resistant to the inhibitory compounds found in crude biological samples. Objectives: 1. Develop a lyophilised assay for direct detection of SARS-CoV-2 from nasal swab samples. 1. Production scaling of a portable instrument for performing the test at Point-of-Need. 2. Demonstration of a pipeline for rapidly deploying new assays in response to future outbreaks and detection from a wider range of sample types. 3. Validation of the assay at 3 independent sites using clinical samples, generating data sets for regulatory approval. Achieving the objectives: BGR has pre-production portable systems in testing for the in-field detection of veterinary diseases from animal nasal swabs. This project will bring scaled production of the product forward by minimally 3 months together with a validated lyophilised SARS-CoV-2 assay. The team has proven experience in diagnostics design and development and will have access to clinical patient samples from Italy and France, generating quantified standards and performance evaluation data that BG Research will document under its ISO13485 quality standard and generate data for MDSAP and hence EUA regulatory approval. Relevance to Work P: The IMI2 call is seeking innovative diagnostics to have impact in combating the current Coronavirus outbreak and this proposal to provide rapid and simplified differential diagnostics at the point of need, is directly aligned with the scope.
Publicationslinked via Europe PMC
Last Updated:43 minutes ago
View all publications at Europe PMC